Drug class
Janus Kinase Inhibitors clinical trials
A class of medicines: the studies that test any of its 52 members, each study once. Members are as MeSH files each medicine’s actions, and as the NCI Thesaurus classes newer ones.
Keep track of what changes. Save the janus kinase inhibitors studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesMedicines in this class
Studies that test each. A study of two counts under both, and once above.
- Filgotinib maleate
- 2
- Flonoltinib maleate
- 2
- Lepzacitinib
- 2
- Frevecitinib
- 2
- Lorpucitinib
- 2
- Ns-018
- 2
- Cerdulatinib
- 2
And 12 more, each tested in fewer studies.
Studies by the year they started
1,424 studies that test it; most in 2026 (133); 4 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 2 |
| 2003 | 3 |
| 2005 | 4 |
| 2007 | 13 |
| 2008 | 19 |
| 2009 | 17 |
| 2010 | 29 |
| 2011 | 31 |
| 2012 | 40 |
| 2013 | 44 |
| 2014 | 55 |
| 2015 | 35 |
| 2016 | 56 |
| 2017 | 71 |
| 2018 | 94 |
| 2019 | 121 |
| 2020 | 118 |
| 2021 | 94 |
| 2022 | 96 |
| 2023 | 125 |
| 2024 | 117 |
| 2025 | 107 |
| 2026 | 133 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 852 · Other 576
Pfizer (170) · Incyte Corporation (119) · Bristol-Myers Squibb (74) · AbbVie (61) · Eli Lilly and Company (56) · Takeda (29) · M.D. Anderson Cancer Center (27) · Galapagos NV (24)
Studies
Open first, then newest update. How each study uses a medicine is read from its arms, and is right about nine times in ten.
Testing one of them · 1,428
- MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia VeraRecruitingPhase 3University of BirminghamNCT04116502Written as Ruxolitinib
- A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque PsoriasisRecruitingPhase 3Bristol-Myers SquibbNCT04772079Written as Deucravacitinib
- Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative NeoplasmsRecruitingPhase 1/2National Cancer Institute (NCI)NCT06303193Written as pacritinib
- A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.RecruitingPhase 2PfizerNCT07219615Written as Ritlecitinib 50 mg
- A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia AreataRecruitingPhase 3PfizerNCT07733765Written as Ritlecitinib 100 mg
- Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic DermatitisRecruitingPhase 1National Institute of Allergy and Infectious Diseases (NIAID)NCT07262983Written as baricitinib
- Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia AreataRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT05398809Written as Ruxolitinib
- Study of Ruxolitinib in Relapsed or Refractory T or NK Cell LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT02974647Written as Ruxolitinib
- A Study to Evaluate the Safety and Effectiveness of Upadacitinib in Pediatric Participants With Alopecia AreataRecruitingPhase 3AbbVieNCT07772492Written as Upadacitinib
- A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in Non-Myeloablative/Reduced Intensity Conditioning Allogeneic Peripheral Blood Stem Cell Transplantation (BMT CTN 2203)RecruitingPhase 3Incyte CorporationNCT06615050Written as Ruxolitinib (Rux)
- daGOAT-Guided Prevention of Severe aGVHD After Allo-HSCTNot yet recruitingPhase 3Institute of Hematology & Blood Diseases Hospital, ChinaNCT07588945Written as Ruxolitinib
- Phase I Trial of Pacritinib in Combination With Venetoclax and Azacitidine for the Treatment of Accelerated and Blast Phase Myeloproliferative NeoplasmsNot yet recruitingPhase 1Roswell Park Cancer InstituteNCT07679334Written as Pacritinib
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic ArthritisRecruitingPhase 3Duke UniversityNCT06654882Written as Tofacitinib
- A Study of Brepocitinib in Adults With Cutaneous SarcoidosisRecruitingPhase 2/3Priovant Therapeutics, Inc.NCT06978725Written as Oral Brepocitinib
- A Study of Zasocitinib in Adults With Non-pustular Palmoplantar PsoriasisNot yet recruitingPhase 3TakedaNCT07752108Written as Zasocitinib
- Safety and Efficacy of Ruxolitinib in Patients With HNSCC and High NLR Treated With Pembrolizumab - The Phase 2 InflammaSTOP TrialNot yet recruitingPhase 2University Hospital, Basel, SwitzerlandNCT07840456Written as Ruxolitinib
- Adaptive Platform Trial for Personnalisation of Sepsis Treatment in Children and Adults: a Multi-national, Treatable Traits-guided, Adaptive, Exploratory, Bayesian Basket TrialRecruitingPhase 2Assistance Publique - Hôpitaux de ParisNCT06381661Written as Baricitinib
- A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative ColitisRecruitingPhase 3Alfasigma S.p.A.NCT06865417Written as Filgotinib
- A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia AreataRecruitingPhase 3PfizerNCT06873945Written as Ritlecitinib 100 mg
- Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALLRecruitingPhase 2/3Bambino Gesù Hospital and Research InstituteNCT07297914Written as Ruxolitinib
See all 1,428 studies that test one of the janus kinase inhibitors →
Codes
What other systems call Janus Kinase Inhibitors · ClinicalTrials.gg INT006642
- MeSH (NLM) D000075242Janus Kinase InhibitorsOne source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000075242 | Janus Kinase Inhibitors | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.